1,788 Shares in Zoetis Inc. (NYSE:ZTS) Bought by 1858 Wealth Management LLC

1858 Wealth Management LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,788 shares of the company’s stock, valued at approximately $349,000.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Asset Dedication LLC boosted its holdings in Zoetis by 4.8% in the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after purchasing an additional 54 shares in the last quarter. Forza Wealth Management LLC raised its stake in Zoetis by 1.8% during the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock worth $574,000 after acquiring an additional 58 shares in the last quarter. L. Roy Papp & Associates LLP lifted its position in Zoetis by 2.8% in the second quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after acquiring an additional 60 shares during the last quarter. Grove Bank & Trust boosted its stake in Zoetis by 0.5% in the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock valued at $2,298,000 after acquiring an additional 61 shares in the last quarter. Finally, Angeles Wealth Management LLC grew its holdings in shares of Zoetis by 3.8% during the first quarter. Angeles Wealth Management LLC now owns 1,702 shares of the company’s stock worth $288,000 after purchasing an additional 62 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 1.6 %

Shares of NYSE ZTS traded down $3.17 during midday trading on Monday, hitting $190.11. The stock had a trading volume of 367,739 shares, compared to its average volume of 2,515,979. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a market capitalization of $86.75 billion, a price-to-earnings ratio of 36.53, a PEG ratio of 3.00 and a beta of 0.89. The company has a fifty day moving average price of $188.98 and a 200 day moving average price of $177.17.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the company posted $1.41 earnings per share. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. On average, analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.14%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Piper Sandler increased their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus increased their target price on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.